Kirkland & Ellis is advising international investment firm BC Partners on the sale of Pharmathen, a leading European pharmaceutical company, to global private markets firm Partners Group (acting on behalf of its clients). The transaction values the business at c. €1.6 billion.
Pharmathen is the leading European drug delivery technology company. With a highly differentiated business model and strong management team, the company is a specialist in the development of "sustained release" technologies, with best-in-class R&D capabilities, serving a blue-chip customer base in nearly 100 countries worldwide. The transaction is subject to receipt of customary regulatory approvals and is expected to close in 2021.
The Kirkland team was led by corporate partners David Higgins, Tom Bartram and associates Victoria Legg, Peter Hyams and Angharad Bainton; tax partner Alan Walker; anti-trust partner Matthew Sinclair-Thomson; debt finance associate Kanesh Balasubramaniam and technology & IP transactions associate John Patten.